Haematocrit targets: Is 45% still the right threshold for phlebotomy?

Polycythaemia vera, a myeloproliferative neoplasm, is characterised by an overproduction of red blood cells, often leading to elevated haematocrit. This increased red cell mass contributes to hyperviscosity, which in turn raises the risk of thrombotic events, including myocardial infarction, stroke, and deep vein thrombosis. The primary goal of treatment, therefore, is to reduce this thrombotic risk, and phlebotomy has long been a cornerstone therapy.

Phlebotomy aims to decrease the red cell mass, thereby lowering blood viscosity and improving blood flow. The procedure involves removing a specific volume of blood, typically 450-500 mL, at regular intervals until the target haematocrit is achieved. This approach effectively reduces the number of circulating red blood cells, but it also induces iron deficiency, which can be both a therapeutic effect (limiting further erythropoiesis) and a source of symptoms for patients.

The historical basis of the 45% target

The 45% haematocrit threshold for phlebotomy in PV patients emerged from clinical observations and early studies that demonstrated a correlation between higher haematocrit levels and increased thrombotic events. The rationale was straightforward: reduce the haematocrit to a level considered 'normal' or near-normal to minimise the risk of blood clots. This target became widely adopted and was incorporated into various national and international guidelines for the management of PV.

But the evidence supporting this precise 45% figure, particularly as a universal target for all PV patients, has been subject to scrutiny. Much of the foundational data predates modern clinical trial methodologies and often involved heterogeneous patient populations. The understanding of PV itself has evolved significantly, with the discovery of the JAK2 V617F mutation and a more complete appreciation of other risk factors, such as age, prior thrombosis, and leukocytosis.

The physiological impact of haematocrit

Haematocrit directly influences blood viscosity. As haematocrit rises, blood becomes thicker, increasing resistance to flow and placing greater strain on the cardiovascular system. This hyperviscosity is a key driver of thrombotic complications in PV. Maintaining haematocrit below a certain level is therefore critical for preventing these events. But the relationship between haematocrit and thrombotic risk is not linear, and the optimal threshold may vary among individuals.

Lowering haematocrit through phlebotomy also induces iron deficiency, which can have its own set of consequences. While mild iron deficiency can be beneficial by suppressing erythropoiesis, severe iron deficiency can lead to symptoms such as fatigue, pica, and restless legs syndrome, significantly impacting a patient's quality of life. Balancing the thrombotic risk reduction with the symptomatic burden of iron deficiency is a constant challenge in PV management.

Phlebotomy as a therapeutic intervention

The procedure of phlebotomy itself is generally well-tolerated, but it is not without potential drawbacks. Repeated phlebotomies can lead to venous access issues, discomfort, and the aforementioned iron deficiency symptoms. The frequency of phlebotomy required to maintain the target haematocrit varies widely among patients, depending on their individual red cell production rates.

Some patients may require phlebotomy every few weeks, while others may only need it a few times a year. This variability highlights the need for an individualised approach to treatment. For patients who require frequent phlebotomies, alternative or adjunctive therapies, such as cytoreductive agents, may be considered to reduce the need for blood removal and alleviate associated symptoms. The management of iron deficiency in other contexts also highlights the complex relationship between iron status and patient well-being.

Considering individual patient factors

The universal application of the 45% haematocrit target may not account for the full spectrum of PV patient characteristics. Patients with a history of thrombosis, for example, may benefit from a more aggressive haematocrit control strategy, potentially aiming for an even lower target. Conversely, patients with a lower baseline thrombotic risk and significant iron deficiency symptoms might tolerate a slightly higher haematocrit if it improves their quality of life without substantially increasing their risk.

Age is another factor. Older patients may have different physiological responses to phlebotomy and iron deficiency compared to younger individuals. Comorbidities, such as cardiovascular disease or chronic kidney disease, also influence the overall risk profile and the tolerability of treatment. A comprehensive assessment of each patient's clinical picture is essential for tailoring the haematocrit target and phlebotomy regimen.

The role of cytoreductive therapy

For many PV patients, particularly those with high-risk features or those who cannot tolerate phlebotomy, cytoreductive agents are an important part of the treatment strategy. Hydroxyurea is a commonly used cytoreductive drug that reduces the production of blood cells, including red blood cells, thereby decreasing the need for phlebotomy and helping to control haematocrit. Other agents, such as interferon alpha and ruxolitinib, are also used in specific patient populations.

The integration of cytoreductive therapy with phlebotomy allows for a more flexible approach to haematocrit management. When cytoreductive agents are effective, the frequency of phlebotomy can often be reduced, alleviating the burden on patients. This combined approach highlights the evolving understanding of PV treatment, moving beyond a single-target strategy to a more holistic management plan. Clinicians often consult resources like the Oxford Handbook of Clinical Haematology for detailed guidance on these complex treatment algorithms.

Unanswered questions and future directions

Despite the long-standing use of the 45% haematocrit threshold, questions remain regarding its optimal application. There is a need for further research, particularly prospective studies, to evaluate whether a more individualised haematocrit target, perhaps guided by a patient's specific risk factors and symptomatic burden, could lead to improved outcomes. Such studies would need to carefully assess both thrombotic event rates and quality of life measures.

The impact of iron deficiency on long-term outcomes, beyond just symptoms, also warrants further investigation. Understanding the precise mechanisms by which different haematocrit levels and iron statuses influence disease progression and complications could refine treatment strategies. The ongoing evolution of diagnostic tools and risk stratification models for PV will also contribute to a more personalised approach to care, potentially moving beyond a one-size-fits-all haematocrit target.

The open-label nature of many historical observations is an obvious caveat. The trial was not powered to detect differences in specific subgroups, and that gap matters for a disease with such a heterogeneous presentation. Whether benefits extend to broader groups of patients with varying comorbidities remains unclear.